Demographics
|
Gender (% Male)
|
58.8
|
67.3
|
0.41
|
Pack years
|
44.5 [10.0–135.0]
|
45 [10.0–220.0]
|
0.53
|
Smoking status (% Current)
|
15.2
|
36.5
|
0.031
|
BMI (Kg/m2)
|
26.1 [20.6–47.0]
|
27.2 [16.5–49.2]
|
0.73
|
FFMI (Kg/m2)
|
17.3 [12.9–28.7]
|
17.6 [10.0–27.0]
|
0.92
|
Chronic bronchitis (%)
|
21.2
|
57.4
|
0.0003
|
Exacerbations (1 year prior)
|
0.0 [0.0–1.0]
|
0.0 [0.0–1.0]
|
0.11
|
Co-morbidities
|
Cardiovascular comorbidity any (%)
|
61.8
|
82.2
|
0.019
|
Comorbidities any (%)
|
35.3
|
16.8
|
0.03
|
Patient reported outcomes
|
SGRQ total
|
19.3 [1.0–40.0]
|
40.9 [5.7–82.4]
|
<0.0001
|
SGRQ symptoms
|
29.5 (16.5)
|
55.3 (17.8)
|
<0.0001
|
SGRQ impact
|
12.0 [3.0–24.0]
|
25.0 [0.0–75.5]
|
<0.0001
|
SGRQ activity
|
34.8 (18.5)
|
58.9 (22.6)
|
<0.0001
|
CAT
|
6.0 [2.0–9.0]
|
16.0 [4.0–39.0]
|
<0.0001
|
CES-D
|
5.0 [1.0–6.0]
|
11.5 [1.0–4.0]
|
<0.0001
|
Functional capacity
|
6MWD (metres)
|
457.0 [169.0–636.0]
|
405.7 [119.0–702.0]
|
0.07
|
Lung function
|
Vital capacity %
|
102.3 (22.5)
|
100.7 (17.9)
|
0.73
|
Total lung capacity %
|
108.9 (16.1)
|
109.2 (20.1)
|
0.96
|
Residual volume %
|
130.6 [89.1–179.9]
|
132.0 [63.0–286.0]
|
0.90
|
Inspiratory capacity %
|
87.1 (23.0)
|
89.5 (21.3)
|
0.65
|
FRC %
|
125.8 (24.0)
|
128.7 (33.2)
|
0.71
|
DLCO %
|
70.8 [56.0–116.5]
|
63.0 [28.0–106.0]
|
0.05
|
KCO %
|
86.8 [64.0–126.5]
|
76.4 [35.0–137.0]
|
0.13
|
VA %
|
84.2 (13.3)
|
80.8 (10.7)
|
0.25
|
Post FEV1 %
|
71.0 (15.2)
|
68.3 (11.4)
|
0.27
|
Reversibility %
|
9.8 [4.0–16.0]
|
6.7 [−3.0–+38.0]
|
0.13
|
Reversibility mls
|
150.0 [−40.0–+290.0]
|
100.0 [−80.0–+670.0]
|
0.21
|
Bacteriology
|
Bacterial load (genome copies/ml)
|
7.11 × 106 [0–1.81 × 1010]
|
7.74 × 104 [0–4.91 × 108]
|
0.29
|
Colonised (% >1 × 104 total PPM)
|
63.7
|
55.6
|
0.75
|
Systemic inflammation
|
CRP (mg/L)
|
3.0 [1.0–22.0]
|
3.0 [1.0–157.0]
|
0.35
|
WBC (109/L)
|
6.8 [3.6–12.0]
|
7.3 [5.0–12.6]
|
0.11
|
Eosinophils (109/L)
|
0.2 [0.0–0.8]
|
0.2 [0.0–0.9]
|
0.83
|